News

Analyzing the levels of a protein called DNASE1L3 may enable an accurate diagnosis of ankylosing spondylitis (AS), a study suggests. Besides being able to distinguish between AS and generalized osteoarthritis, this potential biomarker may also differentiate between active and inactive AS disease. The study, “Serum Deoxyribonuclease…

Mabpharm has filed an application with China’s National Medical Products Administration (NMPA) seeking approval of a biobetter of infliximab, a biological treatment for people with ankylosing spondylitis and other inflammatory disorders. Sorrento Therapeutics, the company owning global rights to the biobetter antibody outside of China,…

Despite experiencing similar symptoms, people with non-radiographic axial spondyloarthritis (nr-axSpA) are less likely to be treated with a biologic therapy than those with ankylosing spondylitis (AS), according to a survey in the U.S. The research was presented in a session, “Comparing Symptoms, Treatments Patterns, and Quality of…

The first ankylosing spondylitis (AS) patient has been dosed in a Phase 3 trial testing SCB-808, a potential biosimilar of Enbrel (etanercept) being developed for the treatment of rheumatic diseases in China. Biosimilars are biological medical products highly similar to a reference product. They are manufactured by…

The efficacy of TNF inhibitors in slowing disease progression in people with ankylosing spondylitis (AS) may be underestimated due to inflammation when treatment is started, new research suggests. The findings were presented in a session, titled “Tumor Necrosis Factor Inhibitors Slow Radiologic Progression in Patients…

Treatment with Taltz (ixekizumab) reduces fatigue and pain in people with ankylosing spondylitis (AS) for up to one year, results from two Phase 3 trials show. The data were discussed at the 2019 American College of Rheumatology/Association for Rheumatology Professionals Annual Meeting in a presentation, titled…

Treatment with Simponi Aria (golimumab) led to clinically meaningful improvements in health-related quality of life in adults with ankylosing spondylitis after four months — benefits that were maintained over one year, a Phase 3 trial shows. The findings were presented in a poster, titled “Effects of…

The U.S. Food and Drug Administration (FDA) has approved Avsola (infliximab-axxq), a biosimilar to Remicade (infliximab), to treat active ankylosing spondylitis, its maker, Amgen, announced. The new therapy has been approved across all diseases that Remicade can treat, which in addition to active ankylosing spondylitis are moderate-to-severe rheumatoid arthritis,…

Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s highest-ranking health official said. “We have to think about how our financing system can protect those with serious and rare illnesses.

Treatment with the anti-rheumatic drug Taltz (ixekizumab) leads to early and sustained reductions in pain, fatigue, and inflammation in people with non-radiographic axial spondyloarthritis (nr-axSpA), a Phase 3 trial shows. It also significantly improves quality of life for these patients, data show. The…